Effect of HCV treatment with DAAs on serum intestinal fatty acid binding protein (I-FABP) as a marker of intestinal permeability in HCV/HIV co-infected patients

Abstract Background HCV and HIV co-infected patients develop cirrhosis more rapidly than mono-infection. Intestinal injury microbial translocation are postulated mechanisms for the rapid progression of cirrhosis. Aim Study effect treatment with DAAs on serum intestinal fatty acid binding protein (I-FABP) as a marker in HCV/HIV its relation to hepatic fibrosis. Comparing level I-FABP mono-infection co-infection was secondary aim. Methods levels were measured 50 non-cirrhotic pre- post-HCV ( SVR 12) (25 naive, 25 HAART) chronic control group. Hepatic fibrosis assessed by FIB4 score, APRI transient elastography. Results had significantly higher compared HCV-mono-infected P = 0.001). After patients, elevated < 0.001) positively correlated baseline values ALT r 0.283, -value 0.047) 0.340, 0.016), respectively. Conclusion is associated subsequent infection epithelial may play role persistence systemic inflammation after eradication.